LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients
Hepatology, 05/17/2012Ito K et al.
The efficacy of LecT–Hepa, a glyco–marker developed using glycoproteomics, for estimating liver fibrosis was demonstrated in a multicenter study. LecT–Hepa given by a combination of the 2 glyco–parameters is a reliable method for determining the fibrosis stage, and is a potential substitute for liver biopsy.
Overall, 183 CHC patients were recruited from 5 liver centers.
The parameters Aspergillus oryzae lectin [AOL]/Dature stramonium lectin [DSA] and Maackia amurensis lectin [MAL]/DSA were measured using a bedside clinical chemistry analyzer in order to calculate LecT-Hepa levels.
The data were compared with those of 7 other noninvasive biochemical markers and tests (hyaluronic acid, tissue inhibitor of metalloproteases-1, platelet count, APRI, Forns index, Fib-4 index, and Zeng's score) for assessing liver fibrosis using the receiver-operating characteristic curve.
LecT-Hepa correlated well with the fibrosis stage as determined by liver biopsy.
The area under the curve (AUC), sensitivity and specificity of LecT-Hepa were 0.802, 59.6%, and 89.9%, respectively, for significant fibrosis; 0.882, 83.3%, and 80.0%, respectively, for severe fibrosis; and 0.929, 84.6%, and 88.5%, respectively, for cirrhosis.
AUC scores of LecT-Hepa at each fibrosis stage were greater than those of the 7 aforementioned noninvasive tests and markers.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.